# A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

> **NCT02965053** · PHASE1 · COMPLETED · sponsor: **Chugai Pharmaceutical** · enrollment: 26 (actual)

## Conditions studied

- Hyperphosphatemia

## Interventions

- **DRUG:** EOS789
- **DRUG:** Placebo
- **DRUG:** Renvela

## Key facts

- **NCT ID:** NCT02965053
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965053, "A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02965053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*